A citation-based method for searching scientific literature

Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng, Suowen Xu. Theranostics 2021
Times Cited: 6







List of co-cited articles
26 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66

Hyperelongated biglycan: the surreptitious initiator of atherosclerosis.
Peter J Little, Narin Osman, Kevin D O'Brien. Curr Opin Lipidol 2008
67
50

Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process.
Peter J Little, Mandy L Ballinger, Micah L Burch, Narin Osman. Open Biochem J 2008
29
50


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50


Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
L J Ignarro, G M Buga, K S Wood, R E Byrns, G Chaudhuri. Proc Natl Acad Sci U S A 1987
33

Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
Arief Rahadian, Daiju Fukuda, Hotimah Masdan Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Masataka Sata. J Atheroscler Thromb 2020
16
33


Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis.
Michael A Gimbrone, Guillermo García-Cardeña. Circ Res 2016
957
33


Inflammation in atherosclerosis.
Peter Libby. Nature 2002
33

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
33

Insulin resistance and atherosclerosis.
Julie Nigro, Narin Osman, Anthony M Dart, Peter J Little. Endocr Rev 2006
221
33

Systemic nature of endothelial dysfunction in atherosclerosis.
T J Anderson, M D Gerhard, I T Meredith, F Charbonneau, D Delagrange, M A Creager, A P Selwyn, P Ganz. Am J Cardiol 1995
233
33


The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
96
33

Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.
Afnan S Alshnbari, Sophie A Millar, Saoirse E O'Sullivan, Iskandar Idris. Diabetes Ther 2020
10
33


Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.
Suowen Xu, Danielle Kamato, Peter J Little, Shinichi Nakagawa, Jaroslav Pelisek, Zheng Gen Jin. Pharmacol Ther 2019
40
33

Endothelial function and dysfunction: Impact of metformin.
Asma Nafisa, Susan G Gray, Yingnan Cao, Tinghuai Wang, Suowen Xu, Feroza H Wattoo, Michael Barras, Neale Cohen, Danielle Kamato, Peter J Little. Pharmacol Ther 2018
40
33

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Guanliang Chen, Eric Mayoux, Shuichi Kaneko, Tsuguhito Ota. EBioMedicine 2017
130
33

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
33

Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.
Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda,[...]. Diabetes Care 2019
20
33

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
33

Novel Treatment of Hypertension by Specifically Targeting E2F for Restoration of Endothelial Dihydrofolate Reductase and eNOS Function Under Oxidative Stress.
Hong Li, Qiang Li, Yixuan Zhang, Wenting Liu, Bo Gu, Taro Narumi, Kin Lung Siu, Ji Youn Youn, Peiqing Liu, Xia Yang,[...]. Hypertension 2019
9
16

Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis.
David C J Howell, Robin H Johns, Joseph A Lasky, Bin Shan, Chris J Scotton, Geoffrey J Laurent, Rachel C Chambers. Am J Pathol 2005
156
16

COVID-19: the vasculature unleashed.
Laure-Anne Teuwen, Vincent Geldhof, Alessandra Pasut, Peter Carmeliet. Nat Rev Immunol 2020
315
16

Effect of unfractionated heparin on endothelial glycocalyx in a septic shock model.
S Yini, Z Heng, A Xin, M Xiaochun. Acta Anaesthesiol Scand 2015
32
16

Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach.
Antonio Cuadrado, Gina Manda, Ahmed Hassan, María José Alcaraz, Coral Barbas, Andreas Daiber, Pietro Ghezzi, Rafael León, Manuela G López, Baldo Oliva,[...]. Pharmacol Rev 2018
196
16



The pivotal role of the endothelium in haemostasis and thrombosis.
P Verhamme, M F Hoylaerts. Acta Clin Belg 2006
58
16

Drug discovery for overcoming chronic kidney disease (CKD): development of drugs on endothelial cell protection for overcoming CKD.
Keisuke Ishizawa, Kunihisa Yamaguchi, Yuya Horinouchi, Yayoi Fukuhara, Soichiro Tajima, Shuichi Hamano, Shuhei Tomita, Koichiro Tsuchiya, Toshiaki Tamaki. J Pharmacol Sci 2009
8
16

Genistein Protects Against Ox-LDL-Induced Inflammation Through MicroRNA-155/SOCS1-Mediated Repression of NF-ĸB Signaling Pathway in HUVECs.
Huaping Zhang, Zhenxiang Zhao, Xuefen Pang, Jian Yang, Haixia Yu, Yinhong Zhang, Hui Zhou, Jiahui Zhao. Inflammation 2017
39
16

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.
Vivian A Fonseca, J Hans Devries, Robert R Henry, Morten Donsmark, Henrik F Thomsen, Jorge Plutzky. J Diabetes Complications 2014
58
16

Noncoding RNAs in Vascular Diseases.
Nicolas Jaé, Stefanie Dimmeler. Circ Res 2020
22
16

Dihydromyricetin increases endothelial nitric oxide production and inhibits atherosclerosis through microRNA-21 in apolipoprotein E-deficient mice.
Dafeng Yang, Zhousheng Yang, Lei Chen, Dabin Kuang, Yang Zou, Jie Li, Xu Deng, Songyuan Luo, Jianfang Luo, Jun He,[...]. J Cell Mol Med 2020
10
16

Critical role of vascular peroxidase 1 in regulating endothelial nitric oxide synthase.
Zhaoya Liu, Yanbo Liu, Qian Xu, Haiyang Peng, Yixin Tang, Tianlun Yang, Zaixin Yu, Guangjie Cheng, Guogang Zhang, Ruizheng Shi. Redox Biol 2017
20
16

Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk S J Opstal, Salem H K The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink,[...]. N Engl J Med 2020
200
16


A chalcone derivative, 1m-6, exhibits atheroprotective effects by increasing cholesterol efflux and reducing inflammation-induced endothelial dysfunction.
Liv Weichien Chen, Min-Chien Tsai, Ching-Yuh Chern, Tien-Ping Tsao, Feng-Yen Lin, Sy-Jou Chen, Pi-Fen Tsui, Yao-Wen Liu, Hsien-Jui Lu, Wan-Lin Wu,[...]. Br J Pharmacol 2020
8
16

Antidiabetic agents and endothelial dysfunction - beyond glucose control.
Linnéa Eriksson, Thomas Nyström. Basic Clin Pharmacol Toxicol 2015
27
16



ACE inhibition lowers angiotensin-II-induced monocyte adhesion to HUVEC by reduction of p65 translocation and AT 1 expression.
Oliver Soehnlein, Alexander Schmeisser, Iwona Cicha, Christine Reiss, Holger Ulbrich, Lennart Lindbom, Werner G Daniel, Christoph D Garlichs. J Vasc Res 2005
34
16

Vascular occlusion by neutrophil extracellular traps in COVID-19.
Moritz Leppkes, Jasmin Knopf, Elisabeth Naschberger, Aylin Lindemann, Jeeshan Singh, Irmgard Herrmann, Michael Stürzl, Léonie Staats, Aparna Mahajan, Christine Schauer,[...]. EBioMedicine 2020
107
16

Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice.
Christian Rask-Madsen, Qian Li, Bryn Freund, Danielle Feather, Roman Abramov, I-Hsien Wu, Kai Chen, Junko Yamamoto-Hiraoka, Jan Goldenbogen, Konstantinos B Sotiropoulos,[...]. Cell Metab 2010
190
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.